Effects of bisphosphonates on isolated Rat osteoclasts as examined by reflected light microscopy
The DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.
Abstract
The bisphosphonates 4-amino-1-hydroxybutylidene-1, 1-bisphosphonic acid (ABP), 3-amino-1, 1-hydroxypropane-1, 1-diphosphonic acid (APD), and 1-hyroxyethane-1, 1-diphosphonic acid (EHDP) were compared for their ability to inhibit the osteoclastic resorption of bone in culture. This was achieved by measuring the effect of bisphosphonate concentration on the number of resorption pits formed and the total area of resorption. During this analysis, a new application of reflected polarized light microscopy was developed that has advantages over other microscopy techniques, including scanning electron microscopy (SEM), as applied to the analysis of resorbed bone surfaces. Based on area analysis, the bisphosphonates were effective for the range 10−7–10−8 M, with ABP about two to five times more effective than EHDP or APD. Similar data were obtained by counting the number of resorption pits but with EC50 10 times higher. At lower concentrations (10−9 M), bisphosphonates may enhance the formation of resorption pits. APD was found to be more toxic (10 times) than ABP or EHDP to osteoclasts and mononuclear cells, but toxic concentrations were at least 102 times higher than the resorption EC50. These data plus immunofluorescence, SEM, and transient incubation experiments show that it is the bisphosphonate-bone complex that directly inhibits the excavation of resorption pits by mature osteoclasts. The mechanism of action does not appear to require inhibition of osteoclast differentiation or toxic elimination of osteoclasts. Bisphosphonates, however, subtly affect the cytoskeleton of osteoclasts
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bisphosphonates do not appear to suppress osteoclastogenesis (129, 140, 141)”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [129]
In the citing paper
“In contrast, bisphosphonates have a different mechanism of action that can be associated with normal or even increased osteoclast numbers despite clear antiresorptive effects (129 -138).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [129]
Citations
Cites
Izzard, C. S., & Lochner, L. R. (1976) · Journal of Cell Science · doi:10.1242/jcs.21.1.129 · Cited by 705
Seaweeds and ulcerative colitis in laboratory animals.
Marcus, R., & Watt, J. (1969) · The Lancet · doi:10.1016/s0140-6736(69)90187-1 · Cited by 427
Resorption of bone by isolated rabbit osteoclasts
Chambers, T. J., Revell, P. A., Fuller, K., & Athanasou, N. A. (1984) · Journal of Cell Science · doi:10.1242/jcs.66.1.383 · Cited by 413
Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix.
Boonekamp, P. M., van der Wee-Pals, L. J. A., LENNEP, M. V., Cw, T., & Bijvoet, O. L. (1986) · PubMed · Cited by 345
Inoué, S. (1986) · Springer eBooks · doi:10.1007/978-1-4757-6925-8 · Cited by 342
Schenk, R., Eggli, P., Fleisch, H., & Rosini, S. (1986) · Calcified Tissue International · doi:10.1007/bf02555748 · Cited by 315
Structure-activity relationships of various bisphosphonates
Shinoda, H., Adamek, G., Felix, R., Fleisch, H., Schenk, R., & Hagan, P. (1983) · Calcified Tissue International · doi:10.1007/bf02405012 · Cited by 306
TREATMENT OF PAGET'S DISEASE WITH (3-AMINO-1-HYDROXYPROPYLIDENE)-1, 1-BISPHOSPHONATE (A.P.D.)
Frijlink, W. B., Bijvoet, O. M., Te Velde, J., & Heynen, G. (1979) · The Lancet · doi:10.1016/s0140-6736(79)91318-7 · Cited by 258
Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases.
Elomaa, I., Blomqvist, C., Gröhn, P., Porkka, L., Kairento, A.-L., Selander, K., Lamberg-Allardt, C., & Holmström, T. (1983) · The Lancet · doi:10.1016/s0140-6736(83)92755-1 · Cited by 209
Quantitative reflection contrast microscopy of living cells.
Bereiter-Hahn, J., Fox, C. H., & Thorell, B. (1979) · The Journal of cell biology · doi:10.1083/jcb.82.3.767 · Cited by 195
Cited by
Items 101–200 of 280
The Role of Muscle Loading on Bone (Re)modeling at the Developing Enthesis
Tatara, A. M., Lipner, J., Das, R., Kim, H. M., Patel, N., Ntouvali, E., Silva, M. J., & Thomopoulos, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097375 · Cited by 50
“Previously, it was believed that alendronate promoted apoptosis in osteoclasts and hence decreased their numbers [21,22].”
BackgroundCafro, A. M., Barbarano, L., Nosari, A., D’Avanzo, G., Nichelatti, M., Bibas, M., Gaglioti, D., Taroni, A., Riva, F. M. G., D’Avanzo, G., et al. (2008) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2008.n.013 · Cited by 48
Şenel, F. Ç., Tekin, U., Durmuş, A., & Bağış, B. (2007) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2006.10.043 · Cited by 47
Sato, Y., Sakai, H., Kobayashi, Y., Shibasaki, Y., & Sasaki, T. (2000) · The Anatomical Record · doi:10.1002/1097-0185(20000901)260:1<72::aid-ar80>3.0.co;2-2 · Cited by 47
“The presence of BP at the site of bone resorption has been considered to be essential for the inhibition of osteoclast functions (Boonekamp et al., 1986; Ralston et al., 1989; Sato et al., 1991; Murakami et al., 1994, 1995; Fleisch, 1997).”
BackgroundBisphosphonate-associated osteonecrosis of the jaw: the rheumatologist's role.
CAPSONI, F., Longhi, M., & Weinstein, R. L. (2006) · Arthritis Research & Therapy · doi:10.1186/ar2050 · Cited by 46
Periprosthetic bone loss: diagnostic and therapeutic approaches
Cavalli, L., & Brandi, M. L. (2013) · F1000Research · doi:10.12688/f1000research.2-266.v2 · Cited by 44
Comparison of Cytotoxic Effects of Bisphosphonates In Vitro and In Vivo
Ito, M., Chokki, M., Ogino, Y., SATOMI, Y., Azuma, Y., Ohta, T., & Kiyoki, M. (1998) · Calcified Tissue International · doi:10.1007/s002239900505 · Cited by 44
“Alendronate (sodium 4-amino-1-hydroxybutilidene-1,1bisphosphonate trihydrate), one of the aminobisphosphonates, is well known as a potent inhibitor of bone resorption mediated by osteoclasts [5, 10, 11].”
BackgroundStructure-activity studies of the s-echistatin inhibition of bone resorption
Sato, M., Garsky, V. M., Majeska, R. J., Einhorn, T. A., Murray, J., Tashjian, A. H., & Gould, R. J. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090917 · Cited by 44
Self-citationBuduneli, E., Vardar, S., Buduneli, N., Berdeli, A., Türkoğlu, O., Başkesen, A., & Atilla, G. (2004) · Journal of Periodontology · doi:10.1902/jop.2004.75.11.1516 · Cited by 43
Bisphosphonates: Mechanisms of Action and Clinical Use
Fleisch, H. A. (1993) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-77991-6_11 · Cited by 43
Bisphosphonates and atypical subtrochanteric fractures of the femur
Kharwadkar, N., Mayne, B., Lawrence, J. E. G., & Khanduja, V. (2017) · Bone and Joint Research · doi:10.1302/2046-3758.63.bjr-2016-0125.r1 · Cited by 42
Ongphiphadhanakul, B., Jenis, L. G., Braverman, L. E., Alex, S., Stein, G. S., Lian, J. B., & Baran, D. T. (1993) · Endocrinology · doi:10.1210/endo.133.6.8243271 · Cited by 42
Effects of Alendronate on Rate of Distraction in Rabbit Mandibles
Tekin, U., Tüz, H. H., Önder, M. E., Özkaynak, Ö., & Korkusuz, P. (2008) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2008.06.023 · Cited by 41
Suzuki, K., Takeyama, S., Sakai, Y., Yamada, S., & Shinoda, H. (2006) · Journal of Pharmacological Sciences · doi:10.1254/jphs.fmj05004x2 · Cited by 40
Owens, J., Fuller, K., & Chambers, T. J. (1997) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(199707)172:1<79::aid-jcp9>3.0.co;2-a · Cited by 40
Sharma, A., Sharma, L. K., & Goyal, R. (2020) · Current Drug Targets · doi:10.2174/1389450121666200910160404 · Cited by 39
Choi, A., Gang, H., Chun, I., & Gwak, H. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.01.050 · Cited by 39
Effect of Topical Administration of Monosodium Olpadronate on Experimental Periodontitis in Rats
Goya, J. A., Paez, H. A., & Mandalunis, P. (2006) · Journal of Periodontology · doi:10.1902/jop.2006.77.1.1 · Cited by 39
Fleisch, H. A., Reszka, A. A., Rodan, G. A., & Rogers, M. J. (2002) · Elsevier eBooks · doi:10.1016/b978-012098652-1/50180-3 · Cited by 39
Ito, M., Azuma, Y., Takagi, H., Komoriya, K., Ohta, T., & Kawaguchi, H. (2002) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.89.255 · Cited by 38
Boyce, B. F., Hughes, D. E., Wright, K. R., Xing, L., & Dai, A. (1998) · Springer eBooks · doi:10.1007/978-3-662-09007-7_3 · Cited by 38
Degradable Bisphosphonate-Alkaline Phosphatase-Complexed Hydroxyapatite Implants In Vitro
Denissen, H. W., van Beek, E. R., van den Bos, T., de Blieck-Hogervorst, J. M. A., Klein, C. P. A. T., & van den Hooff, A. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.2.290 · Cited by 38
Osteoclast recruitment in mice is stimulated by (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate.
Marshall, M. J., Holt, I., & John Davie, M. W. (1993) · Calcified Tissue International · doi:10.1007/bf00675622 · Cited by 37
Cohen, H., Solomon, V., Alferiev, I. S., Breuer, E., Ornoy, A., Patlas, N., Eidelman, N., Hägele, G., & Golomb, G. (1998) · Pharmaceutical Research · doi:10.1023/a:1011990129437 · Cited by 37
Yu, X., Schøller, J., & Foged, N. T. (1996) · Bone · doi:10.1016/s8756-3282(96)00184-6 · Cited by 36
Greiner, S. H., Kadow‐Romacker, A., Wildemann, B., Schwabe, P., & Schmidmaier, G. (2007) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.31444 · Cited by 35
Zoledronic acid in the management of metastatic bone disease
Santini, D., Fratto, M. E., Vincenzi, B., Galluzzo, S., & Tonini, G. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.12.1333 · Cited by 35
“In fact, bisphosphonates affect osteoclast-mediated bone resorption in different ways, including effects on osteoclast differentiation, resorptive activity and viability, but also induction of apoptosis [19].”
BackgroundKatsumi, H., Takashima, M., Sano, J., Nishiyama, K., Kitamura, N., Sakane, T., Hibi, T., & Yamamoto, A. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22620 · Cited by 34
Hypercalcemic complication in patients with oral squamous cell carcinoma
Iwase, M., Takemi, T., MANABE, M., & NAGUMO, M. (2003) · International Journal of Oral and Maxillofacial Surgery · doi:10.1054/ijom.2002.0261 · Cited by 34
Papadaki, H. Α., Tsatsanis, C., Christoforidou, A., Malliaraki, N. E., Psyllaki, M., Pontikoglou, C. G., Miliaki, M., Margioris, A. N., & Eliopoulos, G. D. (2004) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-004-0526-y · Cited by 34
“by cells of the monocyte/macrophage lineage, and inhibit the production of a variety of bone-resorbing cytokines, including TNFα, IL-1� , and IL-6 [ 26 ,31,33].”
BackgroundHistomorphologic characteristics of bisphosphonate‐related osteonecrosis of the jaw
Koerdt, S., Dax, S., Grimaldi, H., Ristow, O., Kuebler, A. C., & Reuther, T. (2014) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12156 · Cited by 34
Mochida, Y., Bauer, T. W., Akisue, T., & Brown, P. R. (2002) · Journal of Bone and Joint Surgery · doi:10.2106/00004623-200202000-00010 · Cited by 33
In vitro resorptive activity of isolated chick osteoclasts: Effects of carbonic anhydrase inhibition
Hunter, S. J., Rosen, C. J., & Gay, C. V. (1991) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650060111 · Cited by 33
Ogawa, K., Hori, M., Takao-Kawabata, R., & SAKURADA, T. (2005) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-005-0612-9 · Cited by 31
“Therefore, in this study, the effects of the administration of elcatonin (a synthetic derivative of eel calcitonin [15–17]) and alendronate (a nitrogen-containing bisphosphonate [18,19]) on the bone of ovariectomized (OVX) rats, which are an animal model of postmenopausal osteoporosis, were evaluated based on the thre…”
MethodEffects of two different bisphosphonates on Paget's disease of bone: ICTP assessed
Filipponi, P., Pedetti, M., Beghe, F., Giovagnini, B., Miam, M. E. U., & Cristallini, S. (1994) · Bone · doi:10.1016/8756-3282(94)90287-9 · Cited by 31
CONSEQUENCES OF NEOPLASIA INDUCED BONE-RESORPTION AND THE USE OF CLODRONATE (REVIEW)
Kanis, J., O'Rourke, N., & McCloskey, E. (1994) · International Journal of Oncology · doi:10.3892/ijo.5.4.713 · Cited by 30
Bone Resorption Inhibitor Alendronate Normalizes the Reduced Bone Thickness of TRPV5−/− Mice
Nijenhuis, T., van der Eerden, B. C. J., Hoenderop, J. G. J., Weinans, H., van Leeuwen, J. P. T. M., & Bindels, R. J. M. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080613 · Cited by 29
Boyce, B. F., Xing, L., Jilka, R. L., Bellido, T., Weinstein, R. S., PARFITT, A. M., & Manolagas, S. C. (2002) · Elsevier eBooks · doi:10.1016/b978-012098652-1.50112-8 · Cited by 29
Balena, R., Markatos, A., Gentile, M., Masarachia, P. J., Seedor, J. G., Rodan, G. A., & Yamamoto, M. (1993) · Bone · doi:10.1016/8756-3282(93)90186-e · Cited by 29
Hoefert, S., Hoefert, C. S., Munz, A., Northoff, H., Yuan, A., Reichenmiller, K., Reinert, S., & Grimm, M. R. (2015) · Clinical Oral Investigations · doi:10.1007/s00784-015-1584-3 · Cited by 28
Combined therapies in osteoporosis: bisphosphonates and vitamin D-hormone analogs.
Schacht, E., Dukas, L., & Richy, F. F. (2007) · PubMed · Cited by 28
The effect of zoledronate on bone remodeling during the healing process
Matos, M. A., Araújo, F. P., & Paixão, F. B. (2007) · Acta Cirúrgica Brasileira · doi:10.1590/s0102-86502007000200007 · Cited by 27
Physiological and Pharmacological Regulation of Biological Calcification
Williams, D. C., & Frolik, C. A. (1991) · International review of cytology · doi:10.1016/s0074-7696(08)60685-3 · Cited by 27
Modulation of PTH-stimulated osteoclastic resorption by bisphosphonates in fetal mouse bone explants
van der Pluijm, G., Löwik, C. W. G. M., de Groot, H., Alblas, M. J., van der Wee-Pals, L. J. A., Bijvoet, O. L. M., & Papapoulos, S. E. (1991) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650061110 · Cited by 26
Katsumi, H., Nakatani, M., Sano, J., Abe, M., Kusamori, K., Kurihara, M., Shiota, R., Takashima, M., Fujita, T., Sakane, T., et al. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.08.041 · Cited by 25
Thaler, R., Spitzer, S. G., Karlic, H., Berger, C., Klaushofer, K., & Varga, F. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.10.016 · Cited by 25
Koshihara, Y., Kodama, S., Ishibashi, H., Azuma, Y., Ohta, T., & Karube, S. (1999) · Journal of Bone and Mineral Metabolism · doi:10.1007/s007740050071 · Cited by 25
“It has been reported that bisphosphonate leads to dramatic changes in osteoclastic morphology [ 5 ,6].”
BackgroundPiper, K., BOYDE, A., & Jones, S. J. (1994) · Calcified Tissue International · doi:10.1007/bf00316291 · Cited by 24
“Jones osteoclast resorption assay have been used to evaluate osteoclast ic function in the presence of b i sphosphona tes [8-11], but there is no information on the effect of bisphosphonates on the resorptive capability of individually identified osteoclasts.”
BackgroundMethodResultInfluentialBuduneli, E., Buduneli, N., Vardar‐Şengül, S., Kardeşler, L., Atilla, G., Lappin, D. F., & Kinane, D. F. (2005) · Journal of Periodontology · doi:10.1902/jop.2005.76.11.1927 · Cited by 24
Gray, A., Davies, M., & Jeffcott, L. B. (2002) · Research in Veterinary Science · doi:10.1053/rvsc.2001.0523 · Cited by 24
Effect of bisphosphonates and gallium on dentin resorption in vitro
LIEWEHR, F., Craft, D. W., Primack, P. D., Kulild, J., Turgeon, D., Sutherland, D. E. R., Schuster, G. S., & Pashley, D. H. (1995) · Dental Traumatology · doi:10.1111/j.1600-9657.1995.tb00674.x · Cited by 24
Cao, Y., Mori, S., Mashiba, T., Kaji, Y., Manabe, T., Iwata, K., Miyamoto, K., Komatsubara, S., & Yamamoto, T. (2006) · Bone · doi:10.1016/j.bone.2006.07.023 · Cited by 23
“Bisphosphonates suppress bone resorption by inhibiting osteoclast activity [27,28], and the continuous long-term use further inhibits osteoclast differentiation [29].”
Yanık, S., Aras, M. H., Erkılıç, S., Bozdağ, Z., Demir, T., & Çetiner, S. (2016) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2015.10.010 · Cited by 23
New therapies for ankylosing spondylitis: etanercept, thalidomide, and pamidronate
Davis, J. C., Huang, F., & Maksymowych, W. P. (2003) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(03)00028-0 · Cited by 23
Therapy for ankylosing spondylitis: new treatment modalities
Braun, J., Bréban, M., & Maksymowych, W. P. (2002) · Best Practice & Research Clinical Rheumatology · doi:10.1053/berh.2002.0245 · Cited by 23
Potential Applications of Biphosphonates in Dental Surgical Implants
Berardi, D., Carlesi, T., Rossi, F., Calderini, M., Volpi, R., & Perfetti, G. (2007) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463200702000304 · Cited by 22
Alendronate therapy in cyclosporine‐induced alveolar bone loss in rats
Spolidório, L. C., Marcantônio, É., Spolidório, D. M. P., Nassar, C. A., Nassar, P. O., Marcantonio, R. A. C., & Rossa, C. (2007) · Journal of Periodontal Research · doi:10.1111/j.1600-0765.2007.00970.x · Cited by 22
Mayahara, M., & Sasaki, T. (2003) · The Anatomical Record Part A Discoveries in Molecular Cellular and Evolutionary Biology · doi:10.1002/ar.a.10092 · Cited by 22
The effect of a bisphosphonate on bone volume and eggshell structure in the hen
Thorp, B. H., Wilson, S., Rennie, S., & Solomon, S. E. (1993) · Avian Pathology · doi:10.1080/03079459308418955 · Cited by 22
Bisphosphonates--targeting bone in the treatment of spondyloarthritis.
Haibel, H., Braun, J., & Maksymowych, W. P. (2002) · PubMed · Cited by 22
Bisphosphonates in development for metabolic bone disease
Sietsema, W. K., & Ebetino, F. H. (1994) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.3.12.1255 · Cited by 21
Gomes, E. W. B., Casarin, M., Martins, T. M., & da Silva, A. F. (2020) · Clinical Oral Investigations · doi:10.1007/s00784-020-03631-8 · Cited by 19
Halvorson, K. G., Sevcik, M. A., Ghilardi, J. R., Sullivan, L. J., Koewler, N. J., Bauss, F., & Mantyh, P. W. (2008) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2007.10.005 · Cited by 19
Relationship between bisphosphonate concentration and osteoclast activity and viability
Rowe, D. J., Etre, L. A., Lovdahl, M. J., & Pietrzyk, D. J. (1999) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-999-0112-7 · Cited by 19
“Several mechanisms have been proposed to explain these effects on the osteoclast: inhibition of osteoclast formation and recruitment (10,14); inhibition of osteoclast activity on bone surface, resuiting from phenomena such as altered ultrastructural features (18,19,23, 34 ,35), reduced proton transport (5,40), and pro…”
BackgroundMatsuda, T., Matsui, K., Shimakoshi, Y., Aida, Y., & Hukuda, S. (1991) · Calcified Tissue International · doi:10.1007/bf02555851 · Cited by 19
“Bisphosphonates inhibit bone resorption through a direct effect on osteoclasts [4, 5] and osteoclast precursors [6, 7].”
BackgroundMecanismos de ação dos bifosfonatos e sua influência no prognóstico do tratamento endodôntico
Sampaio, F. C., Veloso, H. H. P., & Barbosa, D. D. N. (2010) · Revista da Faculdade de Odontologia de Porto Alegre · doi:10.22456/2177-0018.18536 · Cited by 18
Fujita, T., Orimo, H., Inoue, T., Kaneda, K., Sakurai, M., Morita, R., Yamamoto, K., Sugioka, Y., Inoue, A., Takaoka, K., et al. (2007) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-006-0738-4 · Cited by 18
Tamura, Y., Miyakoshi, N., Itoi, E., Abe, T., Kudo, T., Tsuchida, T., Kasukawa, Y., & Satô, K. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.3.541 · Cited by 18
BOYDE, A., & Jones, S. J. (1992) · The Photogrammetric Record · doi:10.1111/j.1477-9730.1992.tb00208.x · Cited by 18
Common mechanism for the estrogen agonist and antagonist activities of droloxifene
GRASSER, W. A., Pan, L. C., Thompson, D. D., & Paralkar, V. M. (1997) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(199705)65:2<159::aid-jcb3>3.0.co;2-t · Cited by 18
Self-citationDevelopment and characterization of a porcine model to study osteoclast differentiation and activity
Galvin, R. J. S., Bryan, P. M., Horn, J. W., Rippy, M. K., & Thomas, J. E. (1996) · Bone · doi:10.1016/8756-3282(96)00178-0 · Cited by 18
The Bisphosphonate Odyssey. A Journey from Chemistry to the Clinic
Graham, R., & Russell, R. G. G. (1999) · Phosphorus, sulfur, and silicon and the related elements · doi:10.1080/10426509908039679 · Cited by 17
Lim, E. J., Kim, J.-T., Kim, C., Kim, J. W., Chang, J. S., & Yoon, P. W. (2019) · Hip & Pelvis · doi:10.5371/hp.2019.31.2.75 · Cited by 17
Pharmacokinetic profile of bisphosphonates in the treatment of metabolic bone disorders.
SINIGAGLIA, L., VARENNA, M., & Casari, S. (2007) · PubMed · Cited by 17
From Polyphosphates to Bisphosphonates and Their Role in Bone and Calcium Metabolism
Fleisch, H. A. (1999) · Progress in molecular and subcellular biology · doi:10.1007/978-3-642-58444-2_10 · Cited by 16
Al‐Azzawi, F. (2008) · Gynecological Endocrinology · doi:10.1080/09513590802296245 · Cited by 16
“Inhibition of protein prenylation of small GTPases disrupts many osteoclastic cellular processes such as loss of the ruffled border of osteoclasts [44], the loss of actin rings and cytoskeletal organization [45].”
Background17β-hydroxywortmannin: A potent inhibitor of bone resorption and phosphatidylinositol-3-kinase
Dodge, J. A., Bryant, H. U., Kim, J., Matter, W. F., Norman, B. H., Srinivasan, U., Vlahos, C. J., & Sato, M. (1995) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/0960-894x(95)00291-z · Cited by 15
Self-citationIto, M., Azuma, Y., Takagi, H., Kamimura, T., Komoriya, K., Ohta, T., & Kawaguchi, H. (2003) · Bone · doi:10.1016/s8756-3282(03)00170-4 · Cited by 15
“Regarding biochemical markers, both plasma OC[1–49] and urinary DPD levels were increased by OVX compared with those in the Sham group, suggesting a high bone turnover state.”
BackgroundMethodInfluentialRole of the bisphosphonate etidronate in the therapy of cancer-related hypercalcemia.
Singer, F. R. (1990) · PubMed · Cited by 15
Galvin, R. J. S., Bryan, P. M., Venugopalan, M., Smith, D. P., & Thomas, J. E. (1998) · Bone · doi:10.1016/s8756-3282(98)00096-9 · Cited by 15
Hou, M., Lee, R. S. B., Du, Z., Hamlet, S. M., Vaquette, C., & Ivanovski, S. (2019) · Journal of Periodontal Research · doi:10.1111/jre.12664 · Cited by 14
Characterization of a New Solvate of Risedronate
Brüning, J., Petereit, A. C., Alig, E., Bolte, M., Dressman, J., & Schmidt, M. U. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22327 · Cited by 14
The Molecular Mechanisms of Action of Bisphosphonates
Thompson, K., & Rogers, M. J. (2007) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-007-9004-0 · Cited by 14
Galli, C., Passeri, G., Cacchioli, A., Gualini, G., Ravanetti, F., Elezi, E., & Macaluso, G. M. (2009) · Journal of Periodontology · doi:10.1902/jop.2009.090152 · Cited by 14
New bone-seeking agent: Animal study of Tc-99m-incadronate
Shigematsu, M., Shiomi, S., Iwao, H., & Ochi, H. (2002) · Annals of Nuclear Medicine · doi:10.1007/bf02995292 · Cited by 13
Yasui, T., Fujita, K., Sasaki, S., Iguchi, M., Hirota, S., Nomura, S., Azuma, Y., Ohta, T., & Kohri, K. (1998) · Urological Research · doi:10.1007/s002400050069 · Cited by 13
“phosphonic acid) is a bisphosphonate causing marked inhibition of bone resorption [1, 28 ].”
BackgroundBantis, A., Zissimopoulos, A., Sountoulides, P., Kalaitzis, C., Giannakopoulos, S., Deftereos, S. P., Tsakaldimis, G., Thomaidis, V. K., & Touloupidis, S. (2011) · Tumori Journal · doi:10.1177/030089161109700411 · Cited by 13
The Biphosphonate Aledronate (MK-217) Inhibits Bone Loss due to Ovariectomy in Rats
Seedor, J. G., Quartuccio, H., & Thompson, D. D. D. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2005.20.2.354 · Cited by 12
Roelofs, A. J., Ebetino, F. H., Reszka, A. A., Russell, R. G. G., & Rogers, M. J. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373884-4.00095-1 · Cited by 13
Bisphosphonate Treatment of Benign Multifocal and Unifocal Osteolytic Tumours of Bone
Gibbons, C. L. M. H., Petra, M., Smith, R., & Athanasou, N. A. (2003) · Sarcoma · doi:10.1080/1357714031000114165 · Cited by 12
“Bisphosphonates are also recognised to have an analgesic effect in bone tumours(5,13) such as LCH where cells within the lesion are known to produce cytokines and prostaglandins which can stimulate progressive osteoclast resorption and pain.(14,15) The analgesic effect of bisphosphonates is explained on the basis that…”
BackgroundIn vitro and in vivo antiresorptive effects of bisphosphonates in metastatic bone disease.
Kanakis, I., Kousidou, O. C., & Karamanos, N. K. (2005) · PubMed · Cited by 12
Myosin II antibodies inhibit the resorption activity of isolated rat osteoclasts
Sato, M., & GRASSER, W. A. (1990) · Cell Motility and the Cytoskeleton · doi:10.1002/cm.970170311 · Cited by 12
Self-citationUltrasound-assisted transdermal delivery of alendronate for the treatment of osteoporosis
Li, B., Huang, G., Ma, Z., & Qin, S. (2020) · Acta Biochimica Polonica · doi:10.18388/abp.2020_5162 · Cited by 11
Bisphosphonates: Mechanisms of Action
Fleisch, H. A. (1998) · Advances in organ biology · doi:10.1016/s1569-2590(08)60154-8 · Cited by 11
Clodronate and Other Bisphosphonates as Supportive Therapy in Osteolysis Due to Malignancy
Elomaa, I., & BLOMQVIST, C. P. (1995) · Acta Oncologica · doi:10.3109/02841869509094039 · Cited by 11
Matsui, A., Kurihara, J., Morishima, H., Suzuki, H., Sato, S., Yamauchi, K., & Takahashi, T. (2015) · Journal of Oral and Maxillofacial Surgery Medicine and Pathology · doi:10.1016/j.ajoms.2015.03.005 · Cited by 10
Xing, Z., Hasty, K. A., & Smith, R. A. (2007) · Journal of Biomedical Materials Research Part B Applied Biomaterials · doi:10.1002/jbm.b.30803 · Cited by 10
Bisphosphonate Mechanisms of Action
Reszka, A. A. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-459-9_19 · Cited by 10
“The changes in the osteoclast are numerous ( 94 ) and include disruption of the cytoskeleton, including actin and vinculin, as well as disruption of the ruffled border (23,28,93,95).”
BackgroundCho, Y. J., Chun, Y. S., Rhyu, K. H., Kang, J. S., Jung, G. Y., & Lee, H. J. (2015) · Hip & Pelvis · doi:10.5371/hp.2015.27.4.258 · Cited by 9
Moran, E. L., Fornasier, V., & Bogoch, E. R. (2000) · Journal of Orthopaedic Research® · doi:10.1002/jor.1100180605 · Cited by 9
Metadata
- Authors
- Sato, M., & Grasser, W.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Sato, Masahiko
- ORCID
- Sato, Masahiko
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 1990-01-01
- Volume
- 5
- Issue
- 1
- Pages
- 31-40
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W1974903174
- Cited by
- 264
- References
- 35
- Citations by year
- 2025: 2 · 2024: 2 · 2023: 3 · 2022: 1 · 2021: 4 · 2020: 3 · 2019: 3 · 2018: 2 · 2017: 2 · 2016: 5 · 2015: 5 · 2014: 6 · 2013: 1 · 2012: 6
- FWCI
- 4.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Journal of Bone and Mineral Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Merck Sharp and Dohme
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Keywords
- bisphosphonates, osteoclasts, bone resorption, 1-hydroxyethane-1,1-diphosphonic acid, resorption pits, bisphosphonate toxicity, mechanism of action
- MeSH terms
- Pamidronate, Animals, Bone Resorption, Cattle, Cell Survival, Diphosphonates, Microscopy, Fluorescence, Microscopy, Phase-Contrast, Microscopy, Polarization, Osteoclasts, Rats, Inbred Strains, Etidronic Acid, Video Recording, Alendronate, Rats, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.